J Korean Orthop Assoc.  2008 Dec;43(6):766-774.

Gene Polymorphism Analysis Related to the Development of Deep Vein Thrombosis

• Song EK
• Seon JK
• Park SJ
• Kim YJ
• Park YH

Abstract

PURPOSE: To determine if the presence of thrombophilic genes affects the development of deep vein thrombosis after total knee arthroplasty (TKA).
MATERIALS AND METHODS
One hundred and forty consecutive patients who underwent primary total knee arthroplasty were enrolled in this study. Preoperatively, all the patients were evaluated for general and hematological risk factors, as well as associated thrombophilic gene polymorphisms. Molecular genetic testing was carried out to detect the following thrombophilic gene polymorphisms: the factor V Leiden mutation, prothrombin promoter G20210A mutation, methylenetetrahydrofolate reductase (MTHFR) C677T, and the plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism.
RESULTS
Deep vein thrombosis was observed in 48 (34%) patients. Regarding the genetic factors, no mutations in factor V Leiden or prothrombin promoter G20210A were detected in any patient regardless of whether they had DVT. The T677T and C677T genotypes of the MTHFR gene had no effect on the development of DVT compared with the C677C genotype. Regarding the PAI-1 gene, the presence of 4G/4G was not associated with an increased risk of DVT. In addition, there was a similar prevalence of the 4G allele in the DVT patients (77%) and controls (84%).
CONCLUSION
Thrombophilic gene polymorphisms do not appear to play an important role in the development of deep vein thrombosis. Therefore, screening tests for these genes will not be useful in determining the risk of deep vein thrombosis in our ethnic patients.

Keyword

Thrombophilic gene; Deep vein thrombosis; Total knee arthroplasty

MeSH Terms

Alleles
Arthroplasty
Factor V
Genotype
Humans
Knee
Mass Screening
Methylenetetrahydrofolate Reductase (NADPH2)
Molecular Biology
Plasminogen Activator Inhibitor 1
Plasminogen Activators
Prevalence
Prothrombin
Risk Factors
Venous Thrombosis
Factor V
Methylenetetrahydrofolate Reductase (NADPH2)
Plasminogen Activator Inhibitor 1
Plasminogen Activators
Prothrombin

Reference

1. Balta G, Altay C, Gurgey A. PAI-1 gene 4G/5G genotype: a risk factor for thrombosis in vessel of internal organs. Am J Hematol. 2002. 71:89–93.

2. Bank I, Libourel EJ, Middeldorp S, et al. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med. 2004. 164:1932–1937.

3. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994. 369:64–67.

4. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation. J Thromb Haemost. 2004. 2:119–127.

5. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993. 268:10739–10745.

6. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost. 2005. 3:1993–1997.

7. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost. 2005. 3:292–299.

8. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995. 10:111–113.

9. Fujimura H, Kambayashi J, Monden M, Kato H, Miyata T. Coagulation factor V Leiden mutation may have a racial background. Thromb Haemost. 1995. 74:1381–1382.

10. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001. 119:Suppl 1. S132–S175.

11. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995. 86:3685–3691.

12. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002. 162:1245–1248.

13. Khaw FM, Moran CG, Pinder IM, Smith SR. The incidence of fatal pulmonary embolism after knee replacement with no prophylactic anticoagulation. J Bone Joint Surg Br. 1993. 75:940–941.

14. Kim TW, Kim WK, Lee JH, et al. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis. J Korean Med Sci. 1998. 13:587–590.

15. Kim YH. The incidence of deep vein thrombosis after cementless and cemented knee replacement. J Bone Joint Surg Br. 1990. 72:779–783.

16. Kim YH, Kim JS. Incidence and natural history of deep-vein thrombosis after total knee arthroplasty. A prospective, randomized study. J Bone Joint Surg Br. 2002. 84:566–570.

17. Kim YH, Suh JS. Low incidence of deep-vein thrombosis after cementless total hip replacement. J Bone Joint Surg Am. 1988. 70:878–882.

18. Ko PS, Chan WF, Siu TH, Khoo J, Wu WC, Lam JJ. Deep vein thrombosis after total hip or knee arthroplasty in a "low-risk" Chinese population. J Arthroplasty. 2003. 18:174–179.

19. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 2000. 342:1792–1801.

20. Koster T, Rosendaal FR, Briët E, et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood. 1995. 85:2756–2761.

21. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and risk of recurrent venous thromboembolism. N Engl J Med. 2000. 343:457–462.

22. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000. 95:1517–1532.

23. Leyvrza PF, Richard J, Bachmann F, et al. Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med. 1983. 309:954–958.

24. Lu Y, Zhao Y, Liu G, et al. Factor V gene G1691A mutation, prothrombin gene G20210A mutation, and MTHFR gene C677T mutation are not risk factors for pulmonary thromboembolism in Chinese population. Thromb Res. 2002. 106:7–12.

25. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000. 342:696–701.

26. Mont MA, Jones LC, Rajadhyaksha AD, et al. Risk factors for pulmonary emboli after total hip or knee arthroplasty. Clin Orthop Relat Res. 2004. 422:154–163.

27. Moser KM. Pulmonary embolism. Am Rev Respir Dis. 1977. 115:829–852.

28. Oger E. Incidence of venous thromboembolism: a community-based study in western France. EPI-GETBP study group. Group d'Etude de la thrombose de bretagne occidentale. Thromb Haemost. 2000. 83:657–660.

29. Patterson BM, Marchand R, Ranawat C. Complications of heparin therapy after total joint arthroplasty. J Bone Joint Surg Am. 1989. 71:1130–1134.

30. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996. 88:3698–3703.

31. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med. 1999. 130:643–650.

32. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk and interaction. Semin Hematol. 1997. 34:171–187.

33. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program. 2005. 1–12.

34. Ryan DH, Crowther MA, Ginsberg JS, Francis CW. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med. 1998. 128:270–276.

35. Sharrock NE, Brien WW, Salvati EA, Mineo R, Garvin K, Sculco TP. The effect of intravenous fixed-dose heparin during total hip arthroplasty on the incidence of deep-vein thrombosis. A randomized, double-blind trial in patients operated on with epidural anesthesia and controlled hypotension. J Bone Joint Surg Am. 1990. 72:1456–1461.

36. Simioni P, Prandoni P, Zanon E, et al. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost. 1996. 76:187–189.

37. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999. 282:2131–2135.

38. Warwick DJ, Whitehouse S. Symptomatic venous thromboembolism after total knee replacement. J Bone Joint Surg Br. 1997. 79:780–786.

39. Westrich GH, Weksler BB, Glueck CJ, Blumenthal BF, Salvati EA. Correlation of thrombophilia and hypofibrinolysis with pulmonary embolism following total hip arthroplasty: an analysis of genetic factors. J Bone Joint Surg Am. 2002. 84:2161–2167.

40. Woolson ST, Zehnder JL, Maloney WJ. Factor V Leiden and the risk of proximal venous thrombosis after total hip arthroplasty. J Arthroplasty. 1998. 13:207–210.